Abstract: Drug discovery is a long process in which only a few successful new therapeutic discoveries are made and identification of drug target candidate proteins requires considerable time and efforts. However, the accumulation of information on drugs has made it possible to devise new computational methods for classifying drug target candidates. In this paper, we devise a Drug Target Protein (DT-P) classification method by the summation of weighted features which is extracted from known DT-P. The method is validated using Bayesian decision theory and SVM, and it was revealed to achieve high specificity of 89.5% with 88% accuracy.
Introduction
Drug Target Protein (DT-P), a protein used for developing a specific drug, has to undergo a long process for finding of a therapeutically relevant disease or for manifestation of safety from a toxic side effect. Since drug must have strong effects on a specific biological pathway and minimally interfere in all other normal metabolisms, confirmation, that a compound inhibits the intended target protein and the identification of undesirable secondary effects are main challenges in developing new drugs (David et al., 2007) . As a result, despite many kinds of drug are already developed, the approved target proteins adopted in drug discovery are just several hundred rather than millions (Wishart et al., 2006; Chan et al., 2001) .
Drug discovery is the process by which drugs are discovered and/or designed (Carnero, 2006) . One of most important steps in the drug discovery process is the identification of candidates (Burbaum and Sigal, 1997) . Immense efforts are spent for this step and countless failures are also made in this step. This indicates that it is very difficult to discover the causes of disease and clarify the process of pathology. Even to researchers who study and have some knowledge on the causes of diseases and their etiological factors, the discovery of anti-disease material is not a simple task. When we consider that it is not possible to figure out all the mechanisms in living cells of a human body (not only in human, also in other living organisms), we cannot expect to find the perfect anti-mechanism of a disease.
The big pharmaceutical companies usually have their own databases of proteins or chemical compounds. In addition, they have the knowledge on finding the causing factors or materials of disease and thus they will be able to find the material, protein, enzyme, or other chemical compounds that act against the factors in their databases (dove 2003) . Such drug discovery processes seem not to be performed by a well-defined logical process, but by a very accidental and fortuitous process. Moreover, the databases of companies do not always provide sufficient information for finding drug target proteins.
There are several bioinformatics tools that have opened up new ways in drug discovery. Nevertheless, we still have to spend time and costs in choosing plausible target proteins from hundreds or thousands of proteins (Xu et al., 2001 ). More tools and techniques need to be developed further. It would be desirable to have a new computational method that can help in classifying or validating drug target candidates efficiently. Fortunately, approved drug target proteins list is opened to public in DrugBank, and annotated features of each protein can be gathered from several resources such as UniProt (Apweiler et al., 2004) , NCBI (1988) , etc. The data has accumulated up to the point allowing one to develop the statistical methods for the classification of Drug Target Proteins based on their annotated features.
Some of research groups attempt to discover new drug target proteins using computational tools or methods. Li and Lai predict drug target proteins using SVM in which the vectors of the machine consist of properties of sequence like residue, hydrophobic, polarity, and other features. The method achieved 80% prediction accuracy in average (Qingliang et al., 2007) . Han et al. also predicts druggable protein which has probability be drug target using SVM. They develop methods which performs over 80% accuracy (Han et al., 2007) .
In this paper, we devise a learning based drug target proteins classification method based on the assumption that drug target proteins may share common features in terms of their structural, functional, or other aspects. In learning stage, we prepare the learning sets for drug target proteins and for Non-Drug Target Proteins (NDT-P) from DrugBank and UniProt, respectively. All features of proteins in learning sets were extracted from UniProt and we assign different weights to each feature based on the number of proteins associated with the features.
Once the weights are assigned to the features, we devise a formula which maps each protein to a reduced integer feature value. By applying the formula to every protein in drug and NDT-P, two distributions are obtained. With these distributions, we reduce the drug target proteins prediction problem to two-category classification problem. Bayesian decision theory and SVM is used in this reduction.
In order to validate the devised formula, we conducted 5-fold cross validation using the data from DrugBank and UniProt. We validated our method using Bayesian decision theory and SVM. According to the evaluation, moderate sensitivity (73.4%) and high specificity (86%) were achieved when we used Bayesian decision theory. Moderate accuracy (85 ~ 90%) and high specificity (93.3%) were achieved by SVM as well. This indicates that if the devised method is used appropriately, it can contribute in reducing the time and cost of the drug discovery process, particularly in the early stage of identifying new drug target proteins.
The rest of the paper is organised as follows. In Section 2, we give brief overview of databases used for learning and test sets. Detailed methods about feature extraction and classification are introduced in Section 3. Validation results are presented in Sections 4 and 5 describes the discussion and analysis of the results. Finally, we draw conclusion with our future plan in Section 6.
Data and materials
For the prediction of Drug Target Proteins, we prepared learning sets of drug target and NDT-P from DrugBank and UniProt databases.
DrugBank is a comprehensive, web-accessible database that brings together quantitative chemical, physical, pharmaceutical and biological data about thousands of well-studied drugs and drug targets (Wishart et al., 2006) . In many points, DrugBank integrates the data-rich molecular biology content that normally found in sequence databases such as UnitProt. DrugBank currently contains nearly 4300 drug entries, corresponding to more than 12000 different trade names and synonyms. Drug entries can be divided in four categories including nearly 1000 FDA-approved small molecule drugs, 113 FDA-approved biotech (protein/peptide) drugs, 62 nutraceuticals and about 3000 experimental drugs (released in 2006). In addition, more than 6000 protein sequences correspond to drug entries. We use the FDA-approved drug target proteins sequences, a list of the sequences of approved drugs' protein targets in DrugBank database.
Although DrugBank provides approved drug target proteins list, it remains only at the sequence level and lacks of annotated features. Since we have to analyse the FASTA sequences of DrugBank to gather features of proteins, we additionally use UniProt database. UniProt (Universal Protein Resource) is popular database provide protein sequences and functional annotations. To map DrugBank proteins to ones of UniProt, sequences are compared. In UniProt, functional property of a certain protein is summarised in 'keywords' annotation, and we use it to make a feature space. A total of 865 kinds of keywords are currently provided in UniProt. Every keyword contains functional property of each protein and one protein may have one or more keywords.
We make two datasets; one is for the drug target proteins and another is for NDT-P. Drug target proteins class consist of 450 proteins, and to check validity proposed method 20% of proteins were reserved as testing data. The same size of NDT-P dataset is randomly selected from UniProt and 20% of them used for testing. Note that duplicated entries were manually removed when we prepare dataset. In this paper, UniProt dataset released 10.4 and approved drug target proteins list of DrugBank published Feburary, 2006 were used.
Methods
In this section, we explain our approach to classify drug proteins and non-drug proteins in terms of weighted features of proteins. The each feature of proteins is distinguished one from others by weight value which is assigned based on devised formula; and a reduced feature value is calculated for each protein using these weights of features. Two distributions for drug and non-drug proteins are obtained respectively based on the reduced feature value. Bayesian decision theory and SVM are used to determine whether an unknown protein is categorised into which distributions.
Feature extraction
UniProt provides many kinds of keywords to specify the characteristics of proteins. In other words, keyword specifies biological features of a protein, and thus it can be used in protein discoveries. Unlike other characteristics like sequence, keyword provides an appropriate level of abstraction for the development of a drug target proteins prediction method using data mining techniques. We use the term feature instead of keyword and we use the two terms alternatively with the same meaning in this paper.
In the first step of our method, we construct feature × protein space. In feature × protein space, if ith protein has jth feature, the value of (i, j) becomes 1, otherwise 0. This space is scalable because we can easily add columns or rows for new features or new proteins. Thus when there are N proteins and M different features in a protein group, the size of feature space becomes N × M. In this paper, we assume that the feature spaces of drug target proteins and general proteins share the same feature list.
Since the number of features reaches several hundreds and the number of proteins reaches several hundreds of feature spaces is quite huge. As a result, it is not a good idea to handle and analyses the feature space of each group in original form. We devise a formula which maps a protein with features to a numerical value as the summary of the characteristics of the protein. Table 1 shows a part of major keywords used in this paper. 
Weighted features for Bayesian decision theory
Since the degree of influences of each feature for a protein to appear in a specific group of proteins could be different, we assign different weight value to each feature. Once the weight assignment is over, the mapping of a protein to a numerical value is rather straightforward. Equation (1) is the devised formula used for the mapping. 
where p is a protein, ω i is ith feature weight and f i is 1 when protein has ith feature otherwise 0. We can consider diverse weight assignment strategies according to situations and classification methods. In this paper, the total number of proteins with a specific feature is the primary factor in deciding the weight for the feature. That is, for each feature, we count the number of proteins with the feature. The number of proteins of a feature is the summation of each column in the original feature space. Then we calculate the differences of each feature, F(ω i ), between two groups (formula (2)). These differences are used as weight factors for the features.
where the result of Diff(i, j) is the difference of i and j, G DT , G NDT represent groups of drug target proteins and NDT-P respectively, and N i (X) is a function that returns the total number of proteins that have ith feature in protein group X. Lastly, we calculate the reduced feature of each protein by formula (1). F(P) is a function that maps a protein p to a reduced feature value. By applying function F(P) to the proteins in DT-P and NDT-P groups, we can obtain two F(P) distributions. Based on the distributions, we develop a drug target proteins classification method for unknown proteins.
Weighted features for SVM
In this subsection, we explain a feature weight assignment method for proteins in SVM. Based on the feature matrix, a feature vector of each protein,
, is reserved by multiplying weights, so it is represented as equation (3) for ith protein. .
The weights are calculated using equation (4). Log (N/n j ) represents how specific the feature is using the total number of proteins N and the number of proteins that have jth feature, n j . If a feature appears frequently and many proteins share the feature, then the feature might not be a representative feature for the protein. Diff j also indicates how well a feature specifies a protein group. Diff j is calculated using equation (5) where GDT j n and GNDT j n represent the numbers of proteins that have jth feature in groups of drug and NDT-P respectively. Therefore, equation (5) is the fraction of differences and a feature must be regarded more important if it appears more frequently in a specific group.
.
Therefore an item of feature vector would have high weight if corresponding keyword rarely appears and yet appears more frequently in one protein group rather than another.
Validation and result
To test the validity of the proposed method, two sets of protein groups were used. One is the approved drug target proteins acquired from DataBank which provides 450 protein sequences. Among the sequences, 80% (360) were used for training, and the others (90) were reserved for testing. On the other hand, the NDT-P group is artificially generated by randomly selecting the reported proteins in UniProt database. Since there is no publicly announced information on the NDT-P, we simply eliminated proteins duplicated in the approved drug target proteins. Another factor that we should regard is the size of NDT-P groups. The fraction of drug target proteins among whole protein in nature is not revealed and also hard to guess by intuition. In this research we extracted NDT-P by the size of the multiple of drug target proteins reserved. This size could affect on prediction accuracy.
Bayesian decision theory
For classification and pattern recognition, there are a variety of decision rules (such as Nearest Neighbour) but only Bayesian decision theory is optimal (Duda et al., 2001; Theodoridis and Koutroumbas, 2006) . Bayesian decision theory is based on the popular Bayesian Rule. Conditional probabilities represent the probability of an event occurring given evidence. Bayesian rule is an expression of conditional probabilities in essence.
is known as likelihood, P(ω i ) is the prior and P(χ)
is evidence. Therefore, Bayesian rule can be represented, likelihood Prior Posterior . evidence
× =
Bayesian decision theory is that if P(χ|ω 1 ) P(ω 1 ) > P(χ|ω 2 ) P(ω 2 ), χ is referred to as ω 1 , otherwise ω 2 . Since Bayesian decision theory use the probability concepts, it can apply when the size of groups are different. Although we randomly select the NDT-P from whole proteins, it is possible to experience with using whole proteins as NDT-P.
A protein p can be classified into drug target proteins class or NDT-P class based on F(p), summation of weighted feature; reduced feature value, and Bayesian decision theory. P(ω 1 ) is a priori probability that next selected protein is drug target proteins, and P(ω 2 ) is a priori probability that the next selected protein is NDT-P. Since we assign the same number of proteins into two groups at first, both of priori probability is 0.5. In addition, P(F(p)|ω 1 ) is probability density function for F(p) given that the state of nature is ω 1 , that is probability of drug target proteins with F(p). Otherwise, P(F(p)|ω 2 ) is the probability of NDT-P with F(p). Therefore, if PF(p)|ω 1 )P(ω 1 ) > PF(p)|ω 2 )P(ω 2 ) satisfies protein P, P is a one of drug target proteins, otherwise NDT-P based on Bayesian decision theory.
For training and testing, the same numbers (450) of randomly selected proteins were used in evaluation with Bayesian decision theory.
In a learning stage, weighted features are firstly acquired from two groups, and reduced feature values, F(p) were calculated for every protein (Section 3.1.1). Figure 1 shows two different distributions acquired after learning stage. Note that x-axis denotes reduced feature value and y-axis denotes a number of proteins respectively. As shown the graph, majority of approved drug target proteins is located near the 500 to 700 F(p) value while it is near 100 to 250 for NDT-P.
In a testing stage, we calculated reduced feature values of test proteins by applying same formula as used for learning set. For each F(p) value, we categorised it to a correspondent distribution by Bayesian Decision Theory. To reduce statistical noise and confirm stability of proposed method, evaluation was performed five times using fivefold cross validation.
In case, since the number of Drug Target Proteins and randomly selected NDT-P are same, the threshold value is 2 2 ( )/ ( ) 1 P P ω ω = . When likelihood ratio 1 2 ( ( ) )/ ( ( ) ) P F p P F p ω ω of P is larger than 1, P is categorised into drug target protein class otherwise N-DTP class.
Figure 1 F( p) Distributions of Drug Target and Non-Drug Target Proteins
As illustrated in Table 2 , we analysed Drug Target Proteins (DT-P) and NDT-P by dividing them into five sections in terms of F(p) value. In first and second section, although there are many numbers of proteins both non-drug target protein and drug target protein, non-drug target proteins are extremely concentrated in these sections. Therefore, sensitivity is low and specificity is high in these sections. In addition, there is difference of number of NDT-P and drug proteins distinctly from 3 to 5 sections, so both sensitivity and specificity is high. However, there is little number of proteins in these sections. Moreover, the average of features in each section is increased with F(p) value, and drug target protein's average of features is bigger than non-drug protein's. We guess this means that drug target proteins have more specific features than NDT-P. 
SVM
We performed five types of prediction experiments with five different number of NDT-P using LibSVM (Fan et al., 2005) . Evaluation was performed by five fold cross validation, so 80% of drug target protein (360) were used for training and the rest 20% was reserved for testing. NDT-P were classified in the same manner. In order to reduce statistical noise and to obtain reliable validation results, we performed the test 20 times with five-fold cross validation for each size of N-DTP groups. (We construct the five type of N-DTP group with different size. The size of N-DTP group is multiplied 1~5 by size of drug target protein group.) After observing results, we decided to use linear kernel for highest accuracy. Table 3 depicts validation results. We experimented in five different (size) ratios of N-DTP to drug target proteins as I already explained. In nature, it is expected that much more number of NDT-P exist than drug target proteins, so we experimented in various leaning sets in which the size of N-DTP group is multiple of that of drug target proteins group. The results show high prediction accuracies at all ratios. At a 1x ratio, all of sensitivity, specificity and accuracy are higher than 80%. However, in 5x ratio, sensitivity is 66.8%, and specificity is 96.5%, and accuracy is 92.4%. That is, if ratio increases, accuracy and specificity also increase, but sensitivity decreases. The reason for the increasing accuracy is that the increase of specificity is more dramatic than the decrease of sensitivity. When we consider that the ratio of N-DTP and drug target protein in nature is unknown, our result is meaningful in the sense that high specificity and sensitivity are achieved. The decreasing sensitivity in the graph means that our method will confront with the difficulty in identifying drug target proteins as the number of NDT-P increases. On the other hand, increasing specificity in the graph means that our method provides a good way to judge N-DTP as the number of NDT-P increases. In addition, if more drug target protein's information becomes available, the prediction accuracy of our method can be improved further.
Discussion
Our dataset of the drug target proteins is relatively smaller than the whole set of proteins. Since we use only 450 proteins for drug target proteins provided from DrugBank database, we use the same number of proteins for N-DTP group rather than using the entire proteins. As a result, we compare only 450 drug target proteins and 450 randomly selected NDT-P. Thus some features may be missing and it could bring a biased result.
We give weights to the factors based on the difference of the numbers of proteins in the two groups. However, the difference is not uniform, and thus it has different value in each randomly selected N-DTP group. For instance, suppose that, two proteins P 1 and P 2 have the same value F(P 1 ) and F(P 2 ), respectively. This does not imply that the two proteins have the same features because weight factors may have the same value for the different features. Our method does not guarantee that each feature is weighted differently. In other words, summation of number of weights is not always distinguishable from all other weights. when protein has ith feature otherwise 0. In order to use distinguished weight values for each factor, we have tried a method to obtain different values between factors in the following way:
According to our experience, the result of classification using these weighted factors was very poor due to the sparsely reduced features. For examples, if we use just 30 weighted features, this weighting method makes 2 32 -1 reduced features. Since our dataset consists of 450 proteins, only 1 or 2 proteins have the same reduced feature. In this case, we have to consider a lot of reduced features and thus drug target proteins and NDT-P are not sufficiently well distinguished.
However, our method developed moderate and reasonable weighted factors and achieved meaningful sensitivity and specificity as shown from the evaluation. It is an open issue if we can develop furthermore accurate weighted factors. In addition, our method regards how the feature is specific for the protein groups in global view because we care about the proportion of feature constitution in each group. Although it does not reflect how much the feature is important in one protein, it will be adequate approach to accommodate local view of features into weighting schemes for system improvements.
As illustrated in Table 2 , most of drug target proteins have much more number of features than those of NDT-P. There are two possibilities; first, since most of drug target proteins are already commercially used in drug, they are studied much more detailed than NDT-P. Second, drug target proteins usually have many features or functions in biologically within real environment. More in-depth study is required to know which case is true. In addition, some of sensitivity and specificity have reached up to 100% and down to Non value. When we consider that achieving 100% sensitivity is not meaningful, we need to carefully analyse the results further. The greater the number of new drug target proteins found, and the more that accurate feature information is added, the more reliable the results we can obtain.
In this paper, we used two classification methods: Bayesian Decision Theory and SVM. Both of them achieved remarkable prediction accuracies using weighted feature values. Since we can use more sophisticated kernel function in SVM, SVM method showed slightly better sensitivity and specificity than Bayesian Decision Theory.
We used 450 drug target proteins, which provided in approved drug target proteins sequence in DrugBank database, and N-DTP groups which is randomly selected from the whole set of proteins. The ratios of N-DTP to drug target proteins were form 1 up to 5. However, actual ratio in nature is unknown. If the ratio of N-DTP to drug target proteins are actually higher than five, than the tendency shown in Figure 2 will continue, and sensitivity could drop further. 
Conclusion and future work
The pharmaceutical industry is still growing, and necessity of computational and logical identification of candidate is gathering strength more. In this paper, we suggest new drug target proteins prediction method using weighted feature value of protein based on annotated features. Validation of our method was performed with Bayesian decision theory and SVM. According to our evaluation, our method shows the meaningful sensitivity, specificity, and accuracy in both validation results. Although the dataset is relatively not enough, we confirmed that there are obvious differences of annotations between drug target proteins and NDT-P. We expect that our approach can be the basic step to figure out the functional properties between drug target proteins and NDT-P. Researcher can avoid unnecessary experiments for discovering new drug target proteins, and they can save time and cost when they know the difference between two groups of proteins. In future, we will enhance prediction method to include more biological meaning. To do that, we will refine weight values of keywords (features) and their relationship under the sense of biological importance, and will assign the weighted factor based on more accurate criteria. In addition, topological properties from physical protein interaction network will be analysed and merged into current method to reduce false positive.
